Advertisement
Screener

INSMED INC (INSM) Operating Expenses

2.8 / 5 stars · 68/120 Roast Me

INSMED INC Operating Expenses

INSMED INC (INSM) reported Operating Expenses of $83.98 million for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-10-30.

Discontinued › Expense Statement › Operating Expenses

us-gaap:OperatingExpenses · last filed 2018-10-30

  • INSMED INC operating expenses for the quarter ending 2018-09-30 was $83.98M, a 90.51% increase year-over-year.
  • INSMED INC operating expenses for the quarter ending 2018-06-30 was $72.88M, a 67.49% increase year-over-year.
  • INSMED INC operating expenses for the quarter ending 2018-03-31 was $62.75M, a 74.46% increase year-over-year.
  • INSMED INC operating expenses for the quarter ending 2017-12-31 was $65.35M, a 2.53% decline year-over-year.
  • INSMED INC operating expenses for fiscal 2017 was $188.92M, a 8.95% increase from fiscal 2016.
  • INSMED INC operating expenses for fiscal 2016 was $173.40M, a 47.58% increase from fiscal 2015.
  • INSMED INC operating expenses for fiscal 2015 was $117.49M, a 34.49% increase from fiscal 2014.
  • INSMED INC operating expenses for fiscal 2014 was $87.36M, a 31.35% increase from fiscal 2013.
Period endOperating Expenses 3 monthOperating Expenses 6 monthOperating Expenses 9 monthOperating Expenses 12 month
2018-09-30$83.98M
10-Q · filed 2018-10-30
$156.87M
derived: sum of 2 quarters · filed 2018-10-30
$219.62M
10-Q · filed 2018-10-30
$284.97M
derived: sum of 4 quarters · filed 2018-10-30
2018-06-30$72.88M
10-Q · filed 2018-08-02
$135.63M
10-Q · filed 2018-08-02
$200.99M
derived: sum of 3 quarters · filed 2018-08-02
$245.07M
derived: sum of 4 quarters · filed 2018-10-30
2018-03-31$62.75M
10-Q · filed 2018-05-02
$128.10M
derived: sum of 2 quarters · filed 2018-05-02
$172.19M
derived: sum of 3 quarters · filed 2018-10-30
$215.70M
derived: sum of 4 quarters · filed 2018-10-30
2017-12-31$65.35M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23
$109.44M
derived: sum of 2 quarters · filed 2018-10-30
$152.95M
derived: sum of 3 quarters · filed 2018-10-30
$188.92M
10-K · filed 2018-02-23
2017-09-30$44.08M
10-Q · filed 2018-10-30
$87.60M
derived: sum of 2 quarters · filed 2018-10-30
$123.57M
10-Q · filed 2018-10-30
$190.62M
derived: sum of 4 quarters · filed 2018-10-30
2017-06-30$43.52M
10-Q · filed 2018-08-02
$79.48M
10-Q · filed 2018-08-02
$146.53M
derived: sum of 3 quarters · filed 2018-08-02
$183.68M
derived: sum of 4 quarters · filed 2018-08-02
2017-03-31$35.97M
10-Q · filed 2018-05-02
$103.02M
derived: sum of 2 quarters · filed 2018-05-02
$140.17M
derived: sum of 3 quarters · filed 2018-05-02
$176.30M
derived: sum of 4 quarters · filed 2018-05-02
2016-12-31$67.05M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23
$104.20M
derived: sum of 2 quarters · filed 2018-02-23
$140.33M
derived: sum of 3 quarters · filed 2018-02-23
$173.40M
10-K · filed 2018-02-23
2016-09-30$37.15M
10-Q · filed 2017-11-02
$73.28M
derived: sum of 2 quarters · filed 2017-11-02
$106.35M
10-Q · filed 2017-11-02
$138.94M
derived: sum of 4 quarters · filed 2018-02-23
2016-06-30$36.13M
10-Q · filed 2017-08-03
$69.20M
10-Q · filed 2017-08-03
$101.79M
derived: sum of 3 quarters · filed 2018-02-23
$132.03M
derived: sum of 4 quarters · filed 2018-02-23
2016-03-31$33.07M
10-Q · filed 2017-05-03
$65.66M
derived: sum of 2 quarters · filed 2018-02-23
$95.90M
derived: sum of 3 quarters · filed 2018-02-23
$123.85M
derived: sum of 4 quarters · filed 2018-02-23
2015-12-31$32.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23
$62.84M
derived: sum of 2 quarters · filed 2018-02-23
$90.79M
derived: sum of 3 quarters · filed 2018-02-23
$117.49M
10-K · filed 2018-02-23
2015-09-30$30.25M
10-Q · filed 2016-11-03
$58.20M
derived: sum of 2 quarters · filed 2016-11-03
$84.90M
10-Q · filed 2016-11-03
$107.97M
derived: sum of 4 quarters · filed 2017-02-23
2015-06-30$27.95M
10-Q · filed 2016-08-04
$54.66M
10-Q · filed 2016-08-04
$77.72M
derived: sum of 3 quarters · filed 2017-02-23
$101.13M
derived: sum of 4 quarters · filed 2017-02-23
2015-03-31$26.71M
10-Q · filed 2016-05-05
$49.77M
derived: sum of 2 quarters · filed 2017-02-23
$73.18M
derived: sum of 3 quarters · filed 2017-02-23
$95.99M
derived: sum of 4 quarters · filed 2017-02-23
2014-12-31$23.07M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23
$46.47M
derived: sum of 2 quarters · filed 2017-02-23
$69.29M
derived: sum of 3 quarters · filed 2017-02-23
$87.36M
10-K · filed 2017-02-23
2014-09-30$23.40M
10-Q · filed 2015-11-06
$46.22M
derived: sum of 2 quarters · filed 2015-11-06
$64.30M
10-Q · filed 2015-11-06
$79.89M
derived: sum of 4 quarters · filed 2016-02-25
2014-06-30$22.82M
10-Q · filed 2015-08-06
$40.90M
10-Q · filed 2015-08-06
$56.49M
derived: sum of 3 quarters · filed 2016-02-25
$73.33M
derived: sum of 4 quarters · filed 2016-02-25
2014-03-31$18.08M
10-Q · filed 2015-05-07
$33.67M
derived: sum of 2 quarters · filed 2016-02-25
$50.52M
derived: sum of 3 quarters · filed 2016-02-25
$70.28M
derived: sum of 4 quarters · filed 2016-02-25
2013-12-31$15.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25
$32.44M
derived: sum of 2 quarters · filed 2016-02-25
$52.20M
derived: sum of 3 quarters · filed 2016-02-25
$66.52M
10-K · filed 2016-02-25
2013-09-30$16.84M
10-Q · filed 2014-11-06
$36.61M
derived: sum of 2 quarters · filed 2014-11-06
$50.92M
10-Q · filed 2014-11-06
$66.76M
derived: sum of 4 quarters · filed 2015-02-27
2013-06-30$19.77M
10-Q · filed 2014-08-06
$34.08M
10-Q · filed 2014-08-06
$49.92M
derived: sum of 3 quarters · filed 2015-02-27
$59.27M
derived: sum of 4 quarters · filed 2015-02-27
2013-03-31$14.31M
10-Q · filed 2014-05-08
$30.15M
derived: sum of 2 quarters · filed 2015-02-27
$39.50M
derived: sum of 3 quarters · filed 2015-02-27
$49.48M
derived: sum of 4 quarters · filed 2015-02-27
2012-12-31$15.84M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27
$25.19M
derived: sum of 2 quarters · filed 2015-02-27
$35.17M
derived: sum of 3 quarters · filed 2015-02-27
$42.44M
10-K · filed 2015-02-27
2012-09-30$9.35M
10-Q · filed 2013-11-05
$19.34M
derived: sum of 2 quarters · filed 2013-11-05
$26.60M
10-Q · filed 2013-11-05
$36.87M
derived: sum of 4 quarters · filed 2014-03-06
2012-06-30$9.98M
10-Q · filed 2013-08-06
$17.25M
10-Q · filed 2013-08-06
$27.52M
derived: sum of 3 quarters · filed 2014-03-06
$62.91M
derived: sum of 4 quarters · filed 2014-03-06
2012-03-31$7.26M
10-Q · filed 2013-05-07
$17.54M
derived: sum of 2 quarters · filed 2014-03-06
$52.93M
derived: sum of 3 quarters · filed 2014-03-06
$64.38M
derived: sum of 4 quarters · filed 2014-03-06
2011-12-31$10.27M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-06
$45.67M
derived: sum of 2 quarters · filed 2014-03-06
$57.12M
derived: sum of 3 quarters · filed 2014-03-06
$66.14M
10-K · filed 2014-03-06
2011-09-30$35.40M
10-Q · filed 2012-11-07
$46.85M
derived: sum of 2 quarters · filed 2012-11-07
$55.86M
10-Q · filed 2012-11-07
$63.51M
derived: sum of 4 quarters · filed 2013-03-18
2011-06-30$11.45M
10-Q · filed 2012-08-07
$20.47M
10-Q · filed 2012-08-07
$28.12M
derived: sum of 3 quarters · filed 2013-03-18
$30.52M
derived: sum of 4 quarters · filed 2013-03-18
2011-03-31$9.02M
10-Q · filed 2012-05-08
$16.67M
derived: sum of 2 quarters · filed 2013-03-18
$19.07M
derived: sum of 3 quarters · filed 2013-03-18
$21.85M
derived: sum of 4 quarters · filed 2013-03-18
2010-12-31$7.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18
$10.06M
derived: sum of 2 quarters · filed 2013-03-18
$12.83M
derived: sum of 3 quarters · filed 2013-03-18
$15.01M
10-K · filed 2013-03-18
2010-09-30$2.40M
10-Q · filed 2011-11-09
$5.18M
derived: sum of 2 quarters · filed 2011-11-09
$7.36M
10-Q · filed 2011-11-09
2010-06-30$2.78M
10-Q/A · filed 2011-08-08
$4.96M
10-Q/A · filed 2011-08-08
2009-12-31$19.05M
10-K · filed 2012-03-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Zoetis Inc. (ZTS)United States$29.045B11.38
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10